The STEP (Semaglutide Treatment Effect in People with obesity) trials, particularly STEP 1, demonstrated not only significant weight loss but also improvements in cardiometabolic risk factors, including lipid parameters
Journal of Obesity & Metabolic Syndrome, 32 (1), 2545
In a landmark 1987 study, Mojsov synthesized GLP-1 and showed, using a perfused rat pancreas model, even tiny doses caused insulin levels to rise in lockstep
Natural pigmentation is impacted by glutathione lightning
The innovations in drug delivery systems and the importance of combining pharmacotherapy with lifestyle changes underscore the dynamic and evolving nature of diabetes care
In clinical trials, patients on the 25mg maintenance dose lost an average of around 13.6% of their body weight over 64 weeks alongside a reduced calorie diet and increased physical activity